Clinical Trials Directory

Trials / Unknown

UnknownNCT01129713

Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE.

Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in Gastroesophageal Reflux Disease(GERD)Patients With Severe Erosive Esophagitis(EE).

Status
Unknown
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
Effexus Pharmaceutical · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

To compare the complete healing of erosive esophagitis(EE) after 3 weeks of treatment with Secretol 80/80 versus Nexium 40 mg daily.

Detailed description

We hypothesize that Secretol 80/80 daily will demonstrate better efficacy than Nexium 40 mg daily in healing erosive esophagitis(EE)and controlling gastroesophageal reflux disease(GERD)related symptoms after 3 weeks of treatment.In addition, Secretol 80/80 daily will have a faster effect on the aforementioned clinical parameters but a similar safety profile.

Conditions

Interventions

TypeNameDescription
DRUGSecretolComparing 80/80 once daily to Nexium once daily in healing erosive esophagitis.
DRUGNexiumComparing 40 mg Nexium once daily to 80/80 Secretol once daily in healing erosive esophagitis.

Timeline

Start date
2010-05-01
Primary completion
2015-05-01
Completion
2015-05-01
First posted
2010-05-25
Last updated
2014-08-05

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01129713. Inclusion in this directory is not an endorsement.